10x Genomics Future Growth
Future criteria checks 1/6
10x Genomics is forecast to grow earnings and revenue by 66% and 11.3% per annum respectively. EPS is expected to grow by 66.5% per annum. Return on equity is forecast to be -7.1% in 3 years.
Key information
66.0%
Earnings growth rate
66.5%
EPS growth rate
| Life Sciences earnings growth | 22.0% |
| Revenue growth rate | 11.3% |
| Future return on equity | -7.1% |
| Analyst coverage | Good |
| Last updated | 27 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 873 | -41 | 19 | 146 | 9 |
| 12/31/2025 | 765 | -118 | -70 | 77 | 15 |
| 12/31/2024 | 668 | -187 | -187 | -12 | 15 |
| 3/31/2024 | 625 | -264 | -74 | -27 | N/A |
| 12/31/2023 | 619 | -255 | -65 | -15 | N/A |
| 9/30/2023 | 591 | -223 | -113 | -27 | N/A |
| 6/30/2023 | 568 | -172 | -118 | -11 | N/A |
| 3/31/2023 | 536 | -174 | -126 | -17 | N/A |
| 12/31/2022 | 516 | -166 | -165 | -34 | N/A |
| 9/30/2022 | 504 | -167 | -161 | -42 | N/A |
| 6/30/2022 | 498 | -142 | -161 | -58 | N/A |
| 3/31/2022 | 499 | -89 | -129 | -38 | N/A |
| 12/31/2021 | 490 | -58 | -123 | -21 | N/A |
| 9/30/2021 | 459 | -455 | -253 | -157 | N/A |
| 6/30/2021 | 406 | -504 | -264 | -187 | N/A |
| 3/31/2021 | 333 | -533 | -289 | -219 | N/A |
| 12/31/2020 | 299 | -543 | -256 | -218 | N/A |
| 9/30/2020 | 262 | -134 | -104 | -81 | N/A |
| 6/30/2020 | 251 | -78 | -46 | -11 | N/A |
| 3/31/2020 | 264 | -49 | -19 | 23 | N/A |
| 12/31/2019 | 246 | -31 | -8 | 35 | N/A |
| 9/30/2019 | 221 | -100 | -62 | -23 | N/A |
| 6/30/2019 | 197 | -105 | -69 | -43 | N/A |
| 3/31/2019 | 170 | -105 | -71 | -57 | N/A |
| 12/31/2018 | 146 | -112 | -83 | -76 | N/A |
| 12/31/2017 | 71 | -19 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1KJ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1KJ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1KJ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1KJ's revenue (11.3% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 1KJ's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1KJ is forecast to be unprofitable in 3 years.